Amarantus has reacquired LymPro Test, MSPrecise, and NuroPro and said that it plans to assign the assets to a new subsidiary.
The flow cytometry-based HIT Confirm test is a first-in-class functional test that provides results in 30 minutes, according to Emosis.
The firm's CEO said that by the end of the year, Celcuity will complete development of new cell-signaling function tests for breast and two other cancer types.
In the third quarter, the firm inked a new lease agreement and completed its initial public offering, receiving aggregate net proceeds of $23.3 million.
The firm had been notified by the exchange in August that it failed to meet a listing requirement calling for a minimum $1 bid price on its stock.
The cell-based diagnostics firm sold a total of 2.76 million shares, including 360,000 shares to the offering's underwriter.
The company is developing a test based on computational quantitation of a subtype cells called MDSCs, which play a role in the tumor microenvironment.
The cancer diagnostics company went public today on the Nasdaq with an initial public offering of 2.4 million shares, priced at $9.50 per share.
The cell-based cancer diagnostics firm said in an SEC filing that it plans to offer 2 million shares of its common stock at between $8 and $10 per share.
Its technology called CELx uses a patient's tumor cells to identify abnormal cellular activity driving their cancer and the most appropriate therapy.